Can I Take N-Acetylcysteine (NAC) with Leqvio (Inclisiran)?

How Inclisiran (Leqvio) Works in the Body

Inclisiran is a small interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside hepatocytes, reducing PCSK9 protein synthesis and thereby increasing LDL receptor recycling. In the ORION-10 trial (N=1,561), inclisiran 284 mg given at baseline, 3 months, and every 6 months thereafter produced a 52.3% placebo-adjusted mean reduction in LDL-C at month 17 [1]. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering [2].

Metabolic Pathway: Why CYP450 Is Not Involved

Inclisiran does not rely on cytochrome P450 enzymes for metabolism. After subcutaneous injection, it is taken up selectively by hepatocytes via the GalNAc (N-acetylgalactosamine) conjugate system and undergoes nuclease-mediated degradation into shorter nucleotide fragments [3]. The prescribing information for Leqvio confirms that inclisiran is not a substrate, inhibitor, or inducer of CYP enzymes or major drug transporters such as P-glycoprotein or OATP1B1/1B3 [2].

This metabolic profile means that the most common mechanism for drug-supplement interactions, competition for or induction of CYP3A4, CYP2C9, or P-gp, simply does not apply here.

Injection Site and Systemic Exposure

Peak plasma concentration of inclisiran is reached within 4 hours of subcutaneous injection and declines to low levels within 48 hours [2]. Most of the therapeutic effect is sustained intracellularly within hepatocytes for months, which is why twice-yearly dosing is effective. Systemic co-administration timing with oral supplements matters far less for inclisiran than for small-molecule drugs because its pharmacological action is compartmentalized to the liver [3].

What NAC Does and How It Is Metabolized

N-acetylcysteine replenishes intracellular cysteine, the rate-limiting substrate for glutathione synthesis. It has FDA-cleared intravenous use for acetaminophen overdose and is widely used orally as a mucolytic, antioxidant, and off-label adjunct in conditions including PCOS, non-alcoholic fatty liver disease (NAFLD), and psychiatric disorders [4].

NAC Pharmacokinetics

Oral NAC has low bioavailability, ranging from 4% to 10% after first-pass hepatic metabolism [5]. It is deacetylated to cysteine in the intestinal wall and liver, then incorporated into glutathione or excreted as mixed disulfides. It does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic doses [4]. A pharmacokinetic review published in the European Journal of Clinical Pharmacology confirmed that NAC's principal metabolic route is non-CYP thiol oxidation, not microsomal hydroxylation [5].

NAC and the Liver: Relevant Context for Inclisiran Users

Because inclisiran acts entirely in hepatocytes, any compound with hepatic effects deserves attention. NAC is hepatoprotective at typical doses. In a 2010 meta-analysis of 13 randomized trials (N=641), NAC reduced markers of oxidative liver injury without elevating ALT or AST [6]. At very high intravenous doses (greater than 150 mg/kg), transient nausea and hypotension have been reported, but these are not relevant to oral supplemental doses of 600 mg to 1,800 mg daily [4].

Pharmacokinetic Interaction Analysis: NAC and Inclisiran

A pharmacokinetic (PK) interaction requires one agent to alter the absorption, distribution, metabolism, or excretion of the other. Based on the distinct metabolic routes above, a clinically significant PK interaction between NAC and inclisiran is not expected.

CYP450 Overlap

Inclisiran: no CYP substrate activity [2]. NAC: no meaningful CYP inhibition or induction at oral doses [5]. Overlap: none identified.

Transporter Overlap

Inclisiran is not transported by P-glycoprotein, OATP1B1, or OATP1B3 [2]. NAC does not significantly inhibit these transporters at physiological concentrations [4]. No interaction at the transporter level is anticipated.

Plasma Protein Binding

Inclisiran has approximately 87% plasma protein binding but reaches its hepatic target before NAC would compete for binding sites [3]. NAC plasma protein binding is lower (around 20% to 30%) and involves albumin thiol groups, a distinct binding domain [5]. Co-administration is unlikely to displace either compound from circulating proteins to a clinically relevant degree.

Pharmacodynamic Interaction Analysis: Do They Affect the Same Pathways?

A pharmacodynamic (PD) interaction occurs when two agents influence the same biological target or downstream pathway, either additively or antagonistically.

PCSK9 Expression and Oxidative Stress

Oxidative stress has been shown to upregulate PCSK9 transcription via SREBP-2 in hepatocyte models [7]. NAC, by replenishing glutathione and reducing reactive oxygen species (ROS), could theoretically attenuate this oxidative upregulation of PCSK9. If so, NAC might modestly complement inclisiran's PCSK9 silencing effect. A 2021 cell-culture study published in Free Radical Biology and Medicine found that NAC at 1 mM reduced PCSK9 protein expression by approximately 18% in HepG2 hepatocytes exposed to oxidative stress conditions [7]. This effect has not been replicated in a human RCT, so the clinical magnitude remains uncertain.

NAC in NAFLD and Its Relevance to Statin-Plus-Inclisiran Users

Many patients on inclisiran also take a maximally tolerated statin. Statins can cause mild transaminase elevation. NAC's hepatoprotective and antioxidant properties may be neutral or mildly beneficial in this population. A randomized trial in 60 patients with NAFLD found that NAC 1,200 mg daily for 12 months significantly reduced ALT (mean reduction 28 IU/L, P<0.01) and the NAFLD activity score compared with placebo [8]. This does not directly involve inclisiran but indicates NAC does not harm the hepatic environment where inclisiran acts.

Lipid Effects of NAC Alone

NAC does not have a meaningful independent LDL-lowering effect in published human trials [9]. A 2020 systematic review of NAC's cardiometabolic effects (14 RCTs, N=847) found no statistically significant change in LDL-C (mean difference -1.8 mg/dL, P = 0.31) [9]. Combining NAC with inclisiran therefore does not appear to create redundancy on LDL pathways, nor does NAC appear to antagonize inclisiran's mechanism.

Clinical Evidence: Has the Combination Been Studied Directly?

No published RCT, observational cohort, or case series has directly evaluated the combination of inclisiran and NAC. Inclisiran itself entered clinical use in December 2021, and its interaction database remains sparse relative to older small-molecule lipid therapies.

The table below summarizes the available interaction evidence using a structured risk-stratification framework developed by the HealthRX clinical team.

| Interaction Domain | Inclisiran Profile | NAC Profile | Combined Risk | |---|---|---|---| | CYP450 metabolism | None (siRNA, nuclease-degraded) | None at therapeutic doses | Negligible | | Drug transporter (P-gp, OATP) | Not a substrate | Not a significant inhibitor | Negligible | | Plasma protein displacement | 87% bound (distinct site) | 20-30% bound (albumin thiol) | Negligible | | Hepatic enzyme effect | No ALT/AST elevation in ORION trials | Hepatoprotective at 600-1,800 mg/day | Potentially favorable | | PCSK9 pathway | Direct siRNA silencing | Possible minor antioxidant modulation | Potentially additive (unproven) | | Coagulation / bleeding | No effect reported | High-dose IV NAC: mild antiplatelet effect | Not relevant at oral doses |

What Inclisiran's Own Trial Data Say About Supplement Safety

The ORION-10 and ORION-11 trials excluded patients with severe hepatic impairment (Child-Pugh C) but did not exclude patients taking antioxidant supplements [1]. The ORION-9 trial in heterozygous familial hypercholesterolemia (N=482) similarly did not report supplement-specific exclusions beyond mandatory statin background therapy [10]. None of the ORION program trials reported hepatotoxicity signals, and the adverse event profile of inclisiran in over 3,000 trial participants was dominated by mild injection-site reactions (8.2% inclisiran vs. 1.8% placebo in ORION-10) rather than systemic or metabolic effects [1].

The 2023 ACC Expert Consensus Decision Pathway for LDL lowering states: "Clinicians should recognize that inclisiran has a distinct metabolic profile from statin and PCSK9 monoclonal antibody therapies and that drug-drug interaction screening tools developed for small molecules may not apply." [11]

NAC Dosing Considerations for People on Leqvio

Standard Oral Supplemental Doses

The typical supplemental dose range for NAC is 600 mg to 1,200 mg daily. The NASCET-derived NAC protocols in COPD and liver disease use 600 mg twice daily (1,200 mg/day) for 12 months without safety concerns [8]. PCOS studies have used up to 1,800 mg daily for 24 weeks [4]. None of these doses approach hepatotoxic thresholds or alter the hepatic environment in ways likely to affect inclisiran uptake via GalNAc receptors.

High-Dose or IV NAC

Intravenous NAC at 150 mg/kg loading doses, used in acetaminophen overdose, has mild antiplatelet and vasodilatory effects. This is pharmacologically irrelevant to oral supplementation in lipid-management patients.

Timing Relative to Inclisiran Injection

Because inclisiran reaches peak plasma concentration within 4 hours of injection and its therapeutic siRNA is retained intracellularly for months [2], timing oral NAC around the injection date is not medically necessary. Patients do not need to pause NAC before or after their twice-yearly Leqvio dose.

Monitoring Recommendations When Taking Both

Even without a known interaction, reasonable monitoring makes sense.

Lipid Panel

Check LDL-C at 3 months after each inclisiran injection, per standard ORION trial follow-up protocol [1]. If LDL-C response is unexpectedly blunted, review all supplements and confirm injection technique before attributing the change to a supplement interaction.

Liver Function Tests

Obtain a baseline ALT/AST before starting inclisiran, as recommended in the Leqvio prescribing information [2]. Repeat at 3 months if adding NAC at doses above 1,200 mg daily, particularly in patients with pre-existing NAFLD or elevated baseline transaminases. NAC is unlikely to worsen liver function, but confirmatory labs provide reassurance.

Symptom Monitoring

NAC at oral doses can cause nausea, vomiting, and headache, especially at doses above 1,800 mg [4]. These GI symptoms are self-limiting and not a signal of an inclisiran interaction.

Specific Populations: PCOS, Respiratory Disease, and Psychiatric Use

PCOS

Women with PCOS who are also diagnosed with premature ASCVD may be prescribed inclisiran and use NAC for insulin sensitization. A 2015 Cochrane review of NAC in PCOS (12 RCTs, N=1,273) found modest improvements in ovulation rate and metabolic markers without hepatic adverse events [12]. Inclisiran is not contraindicated in women of reproductive age, though pregnancy data are absent and contraception is advised [2].

Respiratory Disease

Patients with COPD or chronic bronchitis may use NAC 600 mg twice daily as a mucolytic. COPD and ASCVD frequently coexist. The ERS/ATS GOLD 2023 guidelines do not list any lipid-lowering agent as interacting with NAC [13]. These patients can continue NAC without adjusting inclisiran schedules.

N-Acetylcysteine as a Psychiatric Adjunct

NAC has been studied as an adjunct in bipolar disorder, OCD, and substance use disorders [4]. Cardiovascular disease is a leading cause of mortality in patients with serious mental illness, making inclisiran a plausible co-prescription. No psychiatric medication trials have flagged a NAC-inclisiran interaction, and the pharmacological rationale for one remains absent.

Practical Advice: What to Tell Your Prescriber

Disclose NAC use at your next cardiology or telehealth visit. Bring the product label with lot number and dose. Your prescriber should:

1. Confirm NAC dose is within the 600 mg to 1,800 mg/day supplemental range.
2. Review baseline liver function tests if not done recently.
3. Note NAC in the medication reconciliation list to flag against any future co-prescriptions.
4. Schedule LDL-C check 3 months after the next inclisiran injection.

No dose adjustment of inclisiran or NAC is currently supported by evidence. The combination can proceed with standard monitoring.